Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Essen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologically confirmed non-small cell lung cancer (NSCLC) eligible for anatomic resection (Clinical stages I B, II and selected stage III A)
Eastern Cooperative Oncology Group (ECOG) ≤ 1
Sufficient pulmonary function to undergo curative lung cancer surgery
Adequate hematological, hepatic and renal function parameters:
Sufficient cardiac left ventricular defined as left ventricular ejection fraction (LVEF) ≥ 50% documented either by echocardiography or multigated acquisition scan (MUGA)
Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures
You may not be if
Active or history of autoimmune disease or immune deficiency
Subjects with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration
Subjects who have undergone organ transplant or allogeneic stem cell transplantation
Uncontrolled or significant cardiovascular disease
Patients with active neurological disease
Active malignancy or a prior malignancy within the past 3 years
Receipt of live attenuated vaccine within 30 days prior to the first dose of study medication
Peripheral polyneuropathy NCI CTCAE Grade ≥ 2
History of gastric perforation or fistulae in past 6 months
Serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment.
The patient has undergone major surgery within 28 days prior to enrollment except staging mediastinoscopy, diagnostic Video Assisted Thoracoscopic Surgery (VATS) or implantation of a venous port-system.
Any other concurrent preoperative antineoplastic treatment including irradiation
Pregnant/Breastfeeding women
Subjects with history of severe toxicity or life-threatening toxicity (grade 3 or 4) related to prior immune therapy
Prior treatment with Lymphocyte-activation gene 3 (LAG-3) targeting Agent
Previous treatment with Nivolumab or Relatlimab
Clareo Health | Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
